Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 9/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 9/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 9/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32673039 | 0.87 | GRIN2D (0.33) | SLC9A1 | |
| SCHEMBL32673121 | 0.87 | GRIN2D (0.33) | SLC9A1 | |
| SCHEMBL31298424 | 0.83 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL31298466 | 0.83 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL31298467 | 0.83 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL32673081 | 0.81 | EED (0.34) | EEDSUZ12EZH2CYP3A4CYP2D6 | |
| SCHEMBL32673087 | 0.81 | P2RX7 (0.32) | EEDSUZ12EZH2SLC9A1 | |
| SCHEMBL32673031 | 0.81 | P2RX7 (0.32) | EEDSUZ12EZH2SLC9A1 | |
| SCHEMBL32673033 | 0.77 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL32672807 | 0.77 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2D6CYP2C9ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042769-A1 | TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS | ALCEPTOR THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042769-A1 | TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRB3 | CYP1A2 295/4885EED 4403/4885SUZ12 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.